⚠ Most Biotech Companies Under-Claim R&D Deductions
The enhanced R&D tax deduction (300% on qualifying expenditure) is one of Hong Kong's most valuable incentives, yet most biotech companies claim only the standard deduction or miss qualifying expenditure categories. Proper categorisation of R&D spend is essential.
Common Challenges
Enhanced R&D Deduction
Qualifying R&D expenditure attracts 300% deduction (vs 100% for standard expenses) under s.16B IRO. Identifying qualifying activities and expenditure requires specialist knowledge.
⚠ Risk: Standard deduction only → significant incentive foregone
IP Royalty Structuring
Pharmaceutical IP — patents, drug formulations, clinical data — generates royalty income. The tax treatment depends on where the IP is held and how royalties are structured.
⚠ Risk: Wrong IP structure → full 16.5% tax on all royalty income
Clinical Trial Costs
Clinical trial expenditure in HK vs offshore raises questions of deductibility and offshore income claims. Phase I/II/III trials have different tax treatments.
⚠ Risk: Capitalising all clinical costs → slow deduction write-off
Manufacturing vs R&D Apportionment
Companies with both manufacturing and R&D operations must carefully apportion costs to correctly identify the qualifying R&D component for enhanced deduction purposes.
⚠ Risk: Under-identification of R&D costs → missed enhanced deductions
Who Is This For?
Pharmaceutical companies
Drug manufacturers, pharmaceutical distributors, and generic drug companies.
Biotech startups & scale-ups
Early and growth-stage biotechnology companies doing R&D in HK.
Medical device companies
Medical device manufacturers and developers.
CRO & clinical research
Contract research organisations and clinical research providers.
What We Do
R&D Tax Deduction Optimisation
Identify and document all qualifying R&D expenditure to claim the maximum 300% enhanced deduction under s.16B IRO.
R&D project analysis and qualifying expenditure mapping
IP & Patent Tax Structuring
Structure pharmaceutical IP ownership and licensing to access patent box concessions and minimise royalty withholding tax.
Patent box analysis and IP holding structure review
Pharma/Biotech Profits Tax Return
Prepare BIR51 with enhanced R&D deductions, IP income schedules, and manufacturing/R&D apportionment.
Supporting R&D documentation and cost analysis
Clinical Trial Cost Analysis
Correctly classify clinical trial costs as qualifying R&D expenditure or capital expenditure for tax purposes.
Phase analysis and IRD-defensible treatment documentation
How It Works
R&D Activity Review
2-3 daysAnalyse your R&D programmes, clinical trials, IP portfolio, and manufacturing operations.
Enhanced Deduction Analysis
3-5 daysIdentify qualifying s.16B expenditure and prepare documentation for enhanced deduction claim.
Return Preparation
5-7 daysPrepare profits tax return with R&D deduction schedules and IP income treatment.
Innovation Tax Planning
OngoingOngoing advisory for IP structuring, R&D programme expansion, and grant funding tax treatment.
Case Studies
Biotech startup — drug development, Series A
- •Annual R&D expenditure HKD 12M
- •300% enhanced deduction on HKD 2M qualifying spend
- •Clinical trial costs correctly categorised
- •IP holding structure established
“Their understanding of the R&D tax incentives was exceptional. Significant savings.”
Pharmaceutical distributor — HK & APAC
- •Annual revenue HKD 65M
- •IP royalty structure reviewed
- •Manufacturing vs distribution income split
- •Transfer pricing documentation prepared
“Complex pharma tax handled with expertise and professionalism.”
Frequently Asked Questions
What is the enhanced R&D tax deduction in Hong Kong?
Under s.16B of the IRO, qualifying R&D expenditure attracts a deduction of 300% for the first HKD 2M of qualifying in-house R&D expenditure, and 200% for the remainder. For payments to approved R&D centres, a 100% deduction applies. This is one of Hong Kong's most powerful tax incentives for technology and life sciences companies.
What expenditure qualifies for the enhanced R&D deduction?
Qualifying expenditure includes: staff costs for employees directly engaged in R&D; consumables, reagents, and materials used in R&D; costs of acquiring plant & machinery for R&D (if not otherwise claimed as capital allowances); and fees paid to approved research institutions. The R&D activities must be of a scientific or technology nature and must relate to the company's trade.
Is there a patent box regime in Hong Kong for pharmaceutical IP?
Yes, from 2023 Hong Kong introduced preferential tax treatment for qualifying IP income under the Refined FSIE regime and IP regime. Qualifying patent income can benefit from a reduced effective tax rate. The qualifying IP must be created through substantial R&D activities in HK. Pharmaceutical patents, drug formulations, and medical device patents can potentially qualify.
How are government grants and research funding treated for tax?
Government grants received for R&D activities (e.g., from InnoHK, ITC, or HKSAR government) are generally taxable income if they are revenue in nature and relate to assessable profits. Capital grants for equipment purchase may need to be deducted from the cost of the asset for capital allowance purposes. Overseas grants require case-by-case analysis.
Can clinical trial costs be claimed as enhanced R&D deductions?
Phase I, II, and III clinical trials conducted in Hong Kong can potentially qualify as R&D expenditure under s.16B if they involve systematic investigation aimed at advancing scientific or technical knowledge. The costs must be incurred in HK and directly related to the R&D programme. Clinical trial management fees paid to approved research institutions may also qualify. Detailed record-keeping of trial protocols and expenditure is essential.
需要專業稅務服務？
立即聯繫我們的專業團隊，獲取免費諮詢和報價。我們為個人及企業提供全面的香港稅務服務。
免費諮詢
填寫以下表格，我們的專家團隊將在 24 小時內與您聯繫。